

Laïla-Aïcha Hanafi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10942849/publications.pdf>

Version: 2024-02-01

15
papers

5,535
citations

687363

13
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

6786
citing authors

#	ARTICLE	IF	CITATIONS
1	MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy. PLoS ONE, 2021, 16, e0261987.	2.5	5
2	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nature Communications, 2020, 11, 219.	12.8	167
3	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery, 2017, 7, 1404-1419.	9.4	945
4	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood, 2017, 130, 2295-2306.	1.4	774
5	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. Journal of Clinical Oncology, 2017, 35, 3010-3020.	1.6	568
6	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation, 2016, 126, 2123-2138.	8.2	1,657
7	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine, 2016, 8, 355ra116.	12.4	832
8	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 56-56.	1.4	11
9	Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells. Journal of Clinical Oncology, 2016, 34, 102-102.	1.6	20
10	Fludarabine Downregulates Indoleamine 2,3-Dioxygenase in Tumors via a Proteasome-Mediated Degradation Mechanism. PLoS ONE, 2014, 9, e99211.	2.5	23
11	A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells. Proteomics, 2013, 13, 1108-1120.	2.2	91
12	Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives. Clinical Cancer Research, 2011, 17, 6985-6991.	7.0	343
13	IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. Molecular Immunology, 2011, 49, 253-259.	2.2	31
14	Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine, 2010, 28, 5617-5626.	3.8	21
15	Human Activated T Lymphocytes Modulate IDO Expression in Tumors through Th1/Th2 Balance. Journal of Immunology, 2009, 183, 7752-7760.	0.8	47